|

CPX-351 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Cytarabine, Liposomal daunorubicin, Vyxeos

Pipeline

Phase 1/2: 2

Top Sponsors

  • Masonic Cancer Center, University of Minnesota1
  • Georgetown University1

Indications

  • Cancer2
  • TP531
  • Acute Myeloid Leukemia (AML) in Remission1
  • Acute Myeloid Leukemia1

Washington D.C., District of Columbia1 trial

Phase IB/II of CPX-351 for Relapse Prevention in AML

Georgetown Lombardi Comprehensive Cancer Center

Phase 1/2

Minneapolis, Minnesota1 trial

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Masonic Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.